Literature DB >> 23588873

Genotype-phenotype correlation in MMR mutation-positive families with Lynch syndrome.

Lucía Pérez-Cabornero1, Mar Infante, Eladio Velasco, Enrique Lastra, Cristina Miner, Mercedes Durán.   

Abstract

BACKGROUND: Hereditary nonpolyposis colorectal cancer (HNPCC) is caused by heterozygous mutations in mismatch repair (MMR) genes. Approximately 85 % of genetically defined HNPCC patients have germline mutations in MLH1 and MSH2. HNPCC patients are at increased risk of developing extracolonic cancers. The early age of onset, predominantly right-sided colon cancers, and synchronous and metachronous cancers are other features of the syndrome. HNPCC shows heterogeneous clinical phenotypes, and differences in gene mutation frequencies have been observed in some countries. Several investigators have tried to correlate the phenotype with the affected gene.
METHODS: A total of 46 individuals from 22 unrelated families, of the 264 families fulfilling the inclusion criteria, with deleterious mutations in MLH1, MSH2, or MSH6 genes were identified. We evaluated these clinicopathological features in their relation to different genetic parameters (gene mutated, type of mutation, or alteration of the MMR system in high-risk families) in order to establish a relationship between the phenotype and the genotype in our series.
RESULTS: The phenotype of the disease seems not to be influenced by the type of mutation, but rather by the mutated gene. The presence of multiple tumors is associated with mutations in the MSH2 gene. The mean age at diagnosis of the first colorectal cancer (CRC) was almost identical in families with mutations in MLH1 and MSH2, about 50 years of age, but this age may increase by almost 10 years for MSH6 mutation carriers.
CONCLUSION: The identification of genotype-phenotype correlations could provide a more specific surveillance program focused on the individualized risk.

Entities:  

Mesh:

Year:  2013        PMID: 23588873     DOI: 10.1007/s00384-013-1685-x

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  24 in total

1.  Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer?

Authors:  H F Vasen; H Morreau; J W Nortier
Journal:  Am J Hum Genet       Date:  2001-06       Impact factor: 11.025

2.  Clinicopathologic and pedigree differences in amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status.

Authors:  Laura Valle; Jose Perea; Pablo Carbonell; Victoria Fernandez; Ana M Dotor; Javier Benitez; Miguel Urioste
Journal:  J Clin Oncol       Date:  2007-01-16       Impact factor: 44.544

Review 3.  Deficient DNA mismatch repair: a common etiologic factor for colon cancer.

Authors:  P Peltomäki
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

Review 4.  Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review.

Authors:  H T Lynch; T C Smyrk; P Watson; S J Lanspa; J F Lynch; P M Lynch; R J Cavalieri; C R Boland
Journal:  Gastroenterology       Date:  1993-05       Impact factor: 22.682

5.  Risk of pancreatic cancer in families with Lynch syndrome.

Authors:  Fay Kastrinos; Bhramar Mukherjee; Nabihah Tayob; Fei Wang; Jennifer Sparr; Victoria M Raymond; Prathap Bandipalliam; Elena M Stoffel; Stephen B Gruber; Sapna Syngal
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272

6.  Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.

Authors:  Yvonne M C Hendriks; Anja Wagner; Hans Morreau; Fred Menko; Astrid Stormorken; Franz Quehenberger; Lodewijk Sandkuijl; Pal Møller; Maurizio Genuardi; Hans Van Houwelingen; Carli Tops; Marjo Van Puijenbroek; Paul Verkuijlen; Gemma Kenter; Anneke Van Mil; Hanne Meijers-Heijboer; Gita B Tan; Martijn H Breuning; Riccardo Fodde; Juul Th Wijnen; Annette H J T Bröcker-Vriends; Hans Vasen
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

7.  [Advances in colorectal cancer screening].

Authors:  Rodrigo Jover Martínez
Journal:  Gastroenterol Hepatol       Date:  2008-10       Impact factor: 2.102

8.  Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC).

Authors:  Johanne Geary; Peter Sasieni; Richard Houlston; Louise Izatt; Ros Eeles; Stewart J Payne; Samantha Fisher; Shirley V Hodgson
Journal:  Fam Cancer       Date:  2007-10-16       Impact factor: 2.375

9.  A new strategy to screen MMR genes in Lynch Syndrome: HA-CAE, MLPA and RT-PCR.

Authors:  Lucia Perez-Cabornero; Eladio Velasco; Mar Infante; David Sanz; Enrique Lastra; Lara Hernández; Cristina Miner; Mercedes Duran
Journal:  Eur J Cancer       Date:  2009-02-26       Impact factor: 9.162

10.  Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis.

Authors:  H F Vasen; J T Wijnen; F H Menko; J H Kleibeuker; B G Taal; G Griffioen; F M Nagengast; E H Meijers-Heijboer; L Bertario; L Varesco; M L Bisgaard; J Mohr; R Fodde; P M Khan
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

View more
  9 in total

1.  Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.

Authors:  Mehrdad Zeinalian; Mohammad Hassan Emami; Rasoul Salehi; Azar Naimi; Mohammad Kazemi; Morteza Hashemzadeh-Chaleshtori
Journal:  J Gastrointest Cancer       Date:  2015-06

2.  First description of mutational analysis of MLH1, MSH2 and MSH6 in Algerian families with suspected Lynch syndrome.

Authors:  H Ziada-Bouchaar; K Sifi; T Filali; T Hammada; D Satta; N Abadi
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

3.  The effect of genotypes and parent of origin on cancer risk and age of cancer development in PMS2 mutation carriers.

Authors:  Manon Suerink; Heleen M van der Klift; Sanne W Ten Broeke; Olaf M Dekkers; Inge Bernstein; Gabriel Capellá Munar; Encarna Gomez Garcia; Nicoline Hoogerbrugge; Tom G W Letteboer; Fred H Menko; Annika Lindblom; Arjen Mensenkamp; Pal Moller; Theo A van Os; Nils Rahner; Bert J W Redeker; M J W Olderode-Berends; Maran Olderode; Liesbeth Spruijt; Yvonne J Vos; Anja Wagner; Hans Morreau; Frederik J Hes; Hans F A Vasen; Carli M Tops; Juul T Wijnen; Maartje Nielsen
Journal:  Genet Med       Date:  2015-06-25       Impact factor: 8.822

4.  Immunohistochemical analysis of mismatch repair proteins in Iranian colorectal cancer patients at risk for lynch syndrome.

Authors:  Mehrdad Zeinalian; Mohammad Hassan Emami; Azar Naimi; Rasoul Salehi; Morteza Hashemzadeh-Chaleshtori
Journal:  Iran J Cancer Prev       Date:  2015 Jan-Feb

5.  Shorter telomere length increases age-related tumor risks in von Hippel-Lindau disease patients.

Authors:  Jiang-Yi Wang; Shuang-He Peng; Xiang-Hui Ning; Teng Li; Sheng-Jie Liu; Jia-Yuan Liu; Bao-An Hong; Nie-Nie Qi; Xiang Peng; Bo-Wen Zhou; Jiu-Feng Zhang; Lin Cai; Kan Gong
Journal:  Cancer Med       Date:  2017-08-04       Impact factor: 4.452

Review 6.  The genetic basis of Lynch syndrome and its implications for clinical practice and risk management.

Authors:  Stephanie A Cohen; Anna Leininger
Journal:  Appl Clin Genet       Date:  2014-07-22

7.  Clinical guideline seom: hereditary colorectal cancer.

Authors:  C Guillén-Ponce; R Serrano; A B Sánchez-Heras; A Teulé; I Chirivella; T Martín; E Martínez; R Morales; L Robles
Journal:  Clin Transl Oncol       Date:  2015-11-19       Impact factor: 3.405

8.  A novel heterozygous germline deletion in MSH2 gene in a five generation Chinese family with Lynch syndrome.

Authors:  Bin Wu; Wuyang Ji; Shengran Liang; Chao Ling; Yan You; Lai Xu; Min-Er Zhong; Yi Xiao; Hui-Zhong Qiu; Jun-Yang Lu; Santasree Banerjee
Journal:  Oncotarget       Date:  2017-07-14

9.  Case report of adrenocortical carcinoma associated with double germline mutations in MSH2 and RET.

Authors:  Margarita Raygada; Mark Raffeld; Andrew Bernstein; Markku Miettinen; John Glod; Marybeth S Hughes; Karlyne Reilly; Brigitte Widemann; Jaydira Del Rivero
Journal:  Am J Med Genet A       Date:  2021-02-21       Impact factor: 2.802

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.